Medpace has won a 2018 CRO Leadership Award in the following categories:
- Capabilities (Overall, Big Pharma, Small Pharma)
- Compatibility (Overall, Big Pharma Small Pharma)
- Expertise (Overall, Big Pharma, Small Pharma)
- Quality (Overall, Big Pharma, Small Pharma)
- Reliability (Overall, Big Pharma, Small Pharma)
- Phase IV (Overall)
“Life Science Leader is proud to be working with ISR Reports to honor those CROs that have proven themselves to be the top performers in Compatibility, Capabilities, Expertise, Quality, Reliability, and Phase IV,” said Ed Miseta, Executive Editor, Life Science Leader. “The winners were decided by looking at 20+ different performance metrics, as rated by decision-making executives at bio-pharmaceutical companies. The CROs receiving an award this year are truly at the top of their class, and are deserving of the recognition they receive. Being a top performer in any of these categories shows a level of expertise and commitment to clinical trials and serving the needs of bio-pharmaceutical companies and their patients.”
Medpace will be presented with its CRO Leadership Awards at this year’s DIA Annual Meeting in Boston on June 25.
“Medpace is honored to receive this recognition—especially across so many categories,” commented Jesse Geiger, Chief Operating Officer. “This award is a reflection of our talented people, their dedication to our mission, and a depth of expertise that allows us to carry out complex and scientifically challenging programs. We pride ourselves on our full-service, therapeutically-focused, and scientifically-driven model, which provides the framework that enables us to truly partner with our clients and accelerate their clinical development.”
Medpace also received first place in the ACRP-Avoca CRO Quality Awards earlier this year.